POSTER SESSION |Abstract 6617 | Estimated costs of managing treatment-related adverse events (TRAEs) of nivolumab (nivo) and docetaxel (doc) in the CheckMate 017 and CheckMate 057 phase III non-small cell lung cancer (NSCLC) trials.
Poster Board: #100
Presenter: Meena Venkatachalam
POSTER SESSION | Abstract 2014 | Safety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): Updated results from checkmate-143. Poster Board: #203
Presenter: David A. Reardon, MD
Discussão: 16:45-18.00
ORAL ABSTRACT SESSION| Abstract 3001 | CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC.
Presenter: Matthew David Hellmann, MD
ORAL ABSTRACT SESSION | Abstract 4501 | Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study.
Presenter: Padmanee Sharma, MD, PhD
Chair: Michael T. Halpern, MD, PhD, MPH, University of Arizona College of Public Health
Presentation of the 2016 Partners in Progress Award
Allen S. Lichter, MD, FASCO
Partners in Progress Award
11:30 - 11:45
Susan G. Braun, MA, FASCO
The Assessment and Management of Symptoms in Cancer Survivors
11:45 - 12:05 Mary S. McCabe, RN, MA
Overview of Cancer Survivorship and Current Trends in Care for Cancer Survivorship in the U.S. Compared to Other Countries.
12:05 - 12:25
Michael T. Halpern, MD, PhD, MPH
What Are Survivorship Care Programs/Plans/Models of Care and What Role Do They Play in Addressing Disparities in Oncology Care?
12:25 - 12:45
Mary Ann Burg, PhD, MSW, LCSW
Chair(s): Julie Vose, MD, MBA, FASCO, University of Nebraska Medical Center; Lynn Mara Schuchter, MD, University of Pennsylvania
Presentation of the 2016 Science of Oncology Award
Peter Paul Yu, MD, FACP, FASCO
Presenter: David F. McDermott, MD
Todos os direitos reservados